Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
Aged
Antineoplastic Agents
/ administration & dosage
Carbamazepine
/ administration & dosage
Dose-Response Relationship, Drug
Female
Gabapentin
/ administration & dosage
Humans
Male
Middle Aged
Neurotoxicity Syndromes
/ drug therapy
Oxaliplatin
/ administration & dosage
Peripheral Nervous System Diseases
/ chemically induced
Retrospective Studies
Risk Factors
Tunisia
Chemotherapy
neuropathy
oxaliplatin
toxicity
Journal
The Pan African medical journal
ISSN: 1937-8688
Titre abrégé: Pan Afr Med J
Pays: Uganda
ID NLM: 101517926
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
02
2019
accepted:
11
02
2020
entrez:
16
6
2020
pubmed:
17
6
2020
medline:
29
12
2020
Statut:
epublish
Résumé
The most important limits of oxaliplatin treatment is its peripheral neurotoxicity. The aim of our study was to evaluate the oxaliplatin-induced peripheral neuropathy, its impact on treatment and its management. One hundred chemo-naive patients treated with oxaliplatin-based regimen in the medical oncology department of the military hospital of Tunis between 2012 and 2017 were recruited retrospectively. Evaluation of neuropathy was done according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE V4). Fifty-six patients were aged more than 60 years. The sex-ratio was 1.56. Twenty-seven patients were overweight, 17 were obese and 56 had a BMI inferior to 25 kg/m
Identifiants
pubmed: 32537086
doi: 10.11604/pamj.2020.35.83.18357
pii: PAMJ-35-83
pmc: PMC7250193
doi:
Substances chimiques
Antineoplastic Agents
0
Oxaliplatin
04ZR38536J
Carbamazepine
33CM23913M
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
83Informations de copyright
© Aref Zribi et al.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Support Care Cancer. 2013 May;21(5):1313-9
pubmed: 23196819
BMJ Open. 2015 Apr 01;5(4):e007479
pubmed: 25833669
Clin Colorectal Cancer. 2005 Apr;5 Suppl 1:S38-46
pubmed: 15871765
J Clin Oncol. 2015 Oct 20;33(30):3416-22
pubmed: 26282635
Cancer Chemother Pharmacol. 2009 Oct;64(5):893-9
pubmed: 19189106
Support Care Cancer. 2012 Jul;20(7):1491-7
pubmed: 21814779
Support Care Cancer. 2014 Jul;22(7):1999-2007
pubmed: 24728618
Ginekol Pol. 2018;89(4):200-4
pubmed: 29781075
Asian Pac J Cancer Prev. 2015;16(17):7603-6
pubmed: 26625769
Ann Oncol. 2005 Jun;16(6):869-77
pubmed: 15855226
Support Care Cancer. 2014 Aug;22(8):2281-95
pubmed: 24879391
Clin Colorectal Cancer. 2012 Dec;11(4):275-9
pubmed: 22682776
Neurology. 2006 Dec 26;67(12):2253-5
pubmed: 17190958
Semin Oncol. 2002 Oct;29(5 Suppl 15):21-33
pubmed: 12422305
J Clin Oncol. 2011 Feb 1;29(4):421-7
pubmed: 21189381
J Clin Oncol. 2013 Jul 20;31(21):2699-707
pubmed: 23775951
N Engl J Med. 2004 Jun 3;350(23):2343-51
pubmed: 15175436
J Clin Oncol. 2014 Jun 20;32(18):1941-67
pubmed: 24733808
Ther Clin Risk Manag. 2005 Dec;1(4):249-58
pubmed: 18360567
J Clin Oncol. 2014 Apr 1;32(10):997-1005
pubmed: 24297951
J Clin Oncol. 2003 Jun 1;21(11):2059-69
pubmed: 12775730